RESEARCH 研究の報告

2023.12.2

A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study).

著者 Watanabe S, Furuya N, Nakamura A, Shiihara J, Nakachi I, Tanaka H, Nakao M, Minato K, Seike M, Sasaki S, Kisohara A, Takeuchi S, Honda R, Takamura K, Kagamu H, Yoshimura K, Kobayashi K, Kikuchi T.

ur J Cancer. 2024 Jan;197:113469. doi: 10.1016/j.ejca.2023.113469. Epub 2023 Dec 2.

PMID: 38061214.

2023.8.29

Using the neutrophil-to-lymphocyte ratio to predict the outcome of individuals with nonsquamous non-small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed

著者 Hisao Imai,　Satoshi Wasamoto,　Takeshi Tsuda,　Yoshiaki Nagai,　Takayuki Kishikawa,　Ken Masubuchi,　Takashi Osaki,　Yosuke Miura,　Yukihiro Umeda,　Akihiro Ono,　Hiroyuki Minemura,　Yutaka Yamada,　Junichi Nakagawa,　Yuki Kozu,　Hirokazu Taniguchi,　Hiromitsu Ohta,　Takashi Kasai,　Kyoichi Kaira,　Hiroshi Kagamu.

Thorac Cancer . 2023 Sep;14(25):2567-2578. doi: 10.1111/1759-7714.15036. Epub 2023 Jul 19.

PMID: 37469246 PMCID: PMC10481141 DOI: 10.1111/1759-7714.15036

2023.5.8

Tumor response like pseudo-progression to lenvatinib in advanced thymic carcinoma.

著者 Ito K,　Yamaguchi O,　Kaira K,　Imai H,　Kagamu H.

Lung Cancer . 2023 May:179:107193. doi: 10.1016/j.lungcan.2023.107193. Epub 2023 Apr 10.

PMID: 37058785 DOI: 10.1016/j.lungcan.2023.107193